A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors Conference Paper uri icon

authors

  • Markman, Ben
  • Tran, Ben
  • Gan, Hui
  • Prawira, Amy
  • Coward, Jermaine
  • Jin, Xiaoping
  • Li, Baiyong
  • Wang, Max
  • Xia, Yu
  • Desai, Jayesh
  • Millward, Michael

publication date

  • November 6, 2019